The US Food and Drug Administration (FDA) on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year injectable drug to be used for HIV ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

Patients with HIV receiving 3-drug ART with BIC/FTC/TAF exhibited low rates of viremia, particularly those with high treatment adherence.

And more pharma news updates from Pharmalittle.

A twice-yearly injection of lenacapavir would offer near-complete protection against the virus, clinical date indicate. More pharmaceutical news is about Dupixent, GLP-1 results, and more.